Talabostat is under clinical development by BioXcel Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Talabostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Talabostat overview
Talabostat is under development for the treatment of metastatic castration resistant small cell neuroendocrine prostate cancer (NEPC), metastatic melanoma, metastatic pancreatic ductal adenocarcinoma, acute myelogenous leukemia (AML), and advanced solid cancers. It is administered orally. It targets dipeptidyl peptidase 4, 8 and 9. It is being developed based on artificial intelligence (AI).
It was also under development for the treatment of non-small cell lung cancer, small-cell lung cancer (SCLC), metastatic adenocarcinoma of the pancreas, metastatic melanoma, chronic lymphocytic leukemia, myelodysplastic syndrome, refractory acute myeloid leukemia, relapsed acute myeloid leukemia and relapsed or refractory solid tumors including brain tumors.
BioXcel Therapeutics overview
BioXcel Therapeutics is a commercial-stage biopharmaceutical company focused on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. The company pipeline product portfolio comprises BXCL501, an adrenergic agent with a sublingual route of administration targets neuropsychiatric and neurodegenerative diseases, BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers and BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders. BioXcel Therapeutics‘ drug re-innovation approach leverages existing approved drugs and clinically validated product candidates with big data and proprietary machine learning algorithms to develop new therapeutic candidates. BioXcel Therapeutics is headquartered in New Haven, Connecticut, the US.
For a complete picture of Talabostat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
